Seeking Alpha
Research analyst, IPOs, long/short equity
Profile| Send Message|
( followers)  

The following IPOs are expected to price this week:

Aldeyra Therapeutics (NASDAQ:ALDX), a clinical-stage biotech developing treatments for rare skin and eye diseases, plans to raise $25 million by offering 2.3 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Aldeyra Therapeutics would command a market value of $75 million. Aldeyra Therapeutics, which was founded in 2004, booked $0 million in sales over the last 12 months. The Burlington, MA-based company plans to list on the NASDAQ under the symbol ALDX. Aegis Capital is the lead bookrunner on the deal.

Quotient (NASDAQ:QTNT), which is developing a diagnostics test for grouping and disease screening blood samples, plans to raise $50 million by offering 5.0 million shares at a price range of $9.00 to $11.00. At the midpoint of the proposed range, Quotient would command a market value of $149 million. Quotient, which was founded in 2007, booked $19 million in sales over the last 12 months. The Midlothian, United Kingdom-based company plans to list on the NASDAQ under the symbol QTNT. UBS Investment Bank, Baird and Cowen & Company are the joint bookrunners on the deal. (Revised terms on 4/14/14. Previously planned to offer 5.0mm shares at $14-$16.)

SCYNEXIS (NASDAQ:SCYX), a biotech developing treatments for life-threatening fungal infections, plans to raise $55 million by offering 7.3 million shares at a price range of $7.00 to $8.00. At the midpoint of the proposed range, SCYNEXIS would command a market value of $143 million. SCYNEXIS, which was founded in 1999, booked $17 million in sales over the last 12 months. The Durham, NC-based company plans to list on the NASDAQ under the symbol SCYX. RBC Capital Markets and Canaccord Genuity are the joint bookrunners on the deal. (Revised terms on 4/2/14. Previously planned to offer 4.2mm shares at $12-$14.)

Viggle (NASDAQ:VGGL), a mobile app that rewards users for watching TV and listening to music, plans to raise $50 million by offering 2.1 million shares at a price of $23.50. At the midpoint of the proposed range, Viggle would command a market value of $313 million. Viggle, which was founded in 2011, booked $17 million in sales over the last 12 months. The New York, NY-based company plans to list on the NASDAQ under the symbol VGGL. Ladenburg Thalmann & Co. and Roth Capital are the lead bookrunners on the deal.

Last week, there were 10 IPO pricings. TriVascular Technologies (NASDAQ:TRIV), which markets the smallest and most versatile stent grafts for endovascular aortic repair, was the week's winner, ending up 19% from its IPO price.

Source: 4 U.S. IPOs Planned For The Week Of April 21